The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Herbimycin A Induces the 20 S Proteasome- and Ubiquitin-dependent Degradation of Receptor Tyrosine Kinases
Open accessAbstract
Herbimycin A is an ansamycin antibiotic isolated as an agent that reverses morphological transformation induced by v-src. Although herbimycin A is widely used as a tool for inhibiting multiple tyrosine protein kinases and tyrosine kinase-activated signal transduction, its mechanism of action is not well defined and includes a decrease in both tyrosine kinase protein levels and activity (Uehara, Y., Murakami, Y., Sugimoto, Y., and Mizuno, S. (1989) Cancer Res. 49, 780-785). We now show that herbimycin A induces a profound decrease in the total cellular activity of transmembrane tyrosine kinase receptors, such as insulin-like growth factor, insulin, and epidermal growth factor receptors. A substantial proportion of the in vivo inhibition could be explained by an increase in the rate of degradation. The enhanced degradation of insulin-like growth factor-insulin receptor was prevented by inhibitors of the 20S proteasome, whereas neither lysosomotropic agents nor general serine- and cysteine-protease inhibitors were active in preventing receptor degradation induced by herbimycin A. Moreover, in a temperature-sensitive mutant cell line defective in the E1-catalyzed activation of ubiquitin, herbimycin A treatment at the restrictive temperature did not result in the degradation of insulin receptor. These results suggest that herbimycin A represents a novel class of drug that targets the degradation of tyrosine kinases by the 20S proteasome. The ubiquitin dependence of this process indicates that this degradation of tyrosine kinases might involve the 20S proteasome as the proteolytic core of the ubiquitin-dependent 26S protease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524
Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., & Neckers, L. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.18.8324 · Cited by 1,444
Cited by
Pratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,483
c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor
Levkowitz, G., Waterman, H., Zamir, E., Kam, Z., Oved, S., Langdon, W. Y., Beguinot, L., Geiger, B., & Yarden, Y. (1998) · Genes & Development · doi:10.1101/gad.12.23.3663 · Cited by 865
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
Isaacs, J. S., Jung, Y.-J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204733200 · Cited by 663
Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., & Rosen, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206322200 · Cited by 628
Self-citationUBIQUITIN AND THE CONTROL OF PROTEIN FATE IN THE SECRETORY AND ENDOCYTIC PATHWAYS
Bonifacino, J. S., & Weissman, A. M. (1998) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.14.1.19 · Cited by 613
Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., & Rosen, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29864 · Cited by 511
Self-citationAl-Nasiry, S., Geusens, N., Hanssens, M., Luyten, C., & Pijnenborg, R. (2007) · Human Reproduction · doi:10.1093/humrep/dem011 · Cited by 486
Mimnaugh, E. G., Chavany, C., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.37.22796 · Cited by 466
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
Schneider, C., Sepp-Lorenzino, L., Nimmesgern, E., Ouerfelli, O., Danishefsky, S., Rosen, N., & Hartl, F. U. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14536 · Cited by 405
Self-citationNovobiocin and Related Coumarins and Depletion of Heat Shock Protein 90-Dependent Signaling Proteins
Marcu, M. G., Schulte, T. W., & Neckers, L. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.242 · Cited by 405
The BCR-ABL Story: Bench to Bedside and Back
Wong, S., & Witte, O. N. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104753 · Cited by 399
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.119 · Cited by 336
Lewis, J., Devin, A., Miller, A., Lin, Y., Rodriguez, Y., Neckers, L., & Liu, Z.-G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.14.10519 · Cited by 334
Chemical Inhibitors of Protein Kinases
Bridges, A. J. (2001) · Chemical Reviews · doi:10.1021/cr000250y · Cited by 320
Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity
Neckers, L., Schulte, T. W., & Mimnaugh, E. (1999) · Investigational New Drugs · doi:10.1023/a:1006382320697 · Cited by 301
Chaperones get in touch: the Hip-Hop connection
Frydman, J., & Höhfeld, J. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01005-0 · Cited by 291
Progesterone Receptor Structure and Function Altered by Geldanamycin, an hsp90-Binding Agent
Smith, D. F., Whitesell, L., Nair, S. C., Chen, S., Prapapanich, V., & Rimerman, R. A. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6804 · Cited by 289
Targeting Hsp90: small-molecule inhibitors and their clinical development
Taldone, T., Gozman, A., Maharaj, R., & Chiosis, G. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.015 · Cited by 284
Protein Degradation or Regulation: Ub the Judge
Hochstrasser, M. (1996) · Cell · doi:10.1016/s0092-8674(00)81058-2 · Cited by 279
Chaperones in cell cycle regulation and mitogenic signal transduction: a review
Helmbrecht, K., Zeise, E., & Rensing, L. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00189.x · Cited by 278
Shimamura, T., Lowell, A. M., Engelman, J. A., & Shapiro, G. I. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0933 · Cited by 259
p185erbB2 Binds to GRP94 in Vivo
Chavany, C., Mimnaugh, E., Miller, P., Bitton, R., Nguyen, P., Trepel, J., Whitesell, L., Schnur, R., Moyer, J. D., & Neckers, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.4974 · Cited by 257
Degradation of Connexin43 Gap Junctions Involves both the Proteasome and the Lysosome
Laing, J. G., Tadros, P. N., Westphale, E. M., & Beyer, E. C. (1997) · Experimental Cell Research · doi:10.1006/excr.1997.3747 · Cited by 252
Kusner, D. J., Hall, C. F., & Jackson, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2266 · Cited by 75
Metadata
- Authors
- Sepp-Lorenzino, L., Ma, Z., Lebwohl, D. E., Vinitsky, A., & Rosen, N.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1995-07
- Volume
- 270
- Issue
- 28
- Pages
- 16580-16587
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2080019220
- Cited by
- 189
- References
- 2
- FWCI
- 4.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.